Business Context and Reporting Period
This Form 8-K Current Report was filed by Glaukos Corporation (GKOS) on February 26, 2021, with the earliest event reported on that date. The filing primarily addresses corporate governance changes, specifically the appointment of two new independent directors to the Board of Directors effective March 1, 2021.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointments: Dr. Leana S. Wen was appointed as a Class III director (serving until the 2021 Annual Meeting), and Denice M. Torres was appointed as a Class II director (serving until the 2023 Annual Meeting).
- Independence: Both new directors are deemed independent under NYSE rules, resulting in eight of the nine directors being independent.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Management noted that committee assignments for the new directors are expected but have not yet been determined. The filing confirms that no special arrangements or understandings existed regarding the appointments and that the directors will receive standard compensation for non-employee directors.
Investor Verification Checklist
- Verify the specific committee assignments for Dr. Wen and Ms. Torres in subsequent filings.
- Review the Company's standard compensation program for non-employee directors referenced in the May 7, 2020 Form 10-Q (Exhibit 10.2).
- Confirm the press release details furnished as Exhibit 99.1 for any additional context on the appointments.